We report a patient with unusual cutaneous manifestations of Behc;et's disease and antineutrophil cytoplasmic antibodies (ANCA) directed against the cytotoxic protein, bactericidal/permeability-increasing protein (BPI). This is the first report of Behc;et's disease associated with this autoantibody.
CASE HISTORY
A 28-year old Caucasian male presented with a three month history of an asymptomatic, erythematous rash initially confined to his feet, but with subsequent spread to involve most of the skin. Over the same period he had lost 6.5 kg (141b) in weight and also developed mild arthralgia of the small joints of his hands and feet. He also developed a sore throat and had a history of recurrent tonsillitis, for which a tonsillectomy had been recommended, but not yet performed. He was on no regular medication.
Examination, at presentation, revealed tonsillitis and a widespread cutaneous erythema. Skin biopsy demonstrated a non-specific, mild upper dermal perivascular mononuclear cell infiltrate. The ASOT was 300 III (normal <200IU) and a throat swab isolated Streptococcus Group G. Full blood count, erythrocyte sedimentation rate and biochemistry were normal. Occasional neutrophils, leukocytoclasia and red blood cell extravasation were present, consistent with a leukocytoclastic vasculitis. Direct immunofluorescence revealed C3 and IgM within blood vessel walls. An initial vasculitis screen was negative although 5 months later cANCA were detected by indirect immunofluorescence. Using Western blotting the patient's serum bound to a 55 kD protein, subsequently identified as BPI, but not to either proteinase-3 (PR3) or myeloperoxidase (MPO).
One month later he was admitted as an emergency with severe rectal bleeding, from ulcers in the anal canal and transverse colon, resulting in a 4 gl dl drop in haemoglobin.
A radiolabelled indium white cell scan (to look for evidence of systemic involvement) demonstrated involvement of both the genitalia and lungs consistent with active vasculitis. He was treated with prednisolone, initially 40mg daily, and thalidomide, 100 mg daily, with resolution of his symptoms.
DISCUSSION
The diagnosis of Behcet's disease is made purely on clinical criteria because no pathognomonic laboratory test exists. Although our patient's initial cutaneous presentation of erythema, without vasculitis, was unusual his disease evolved to subsequently fulfill the diagnostic criteria of Behcet's disease".
The aetiology and pathogenesis of Behcet's disease are unknown but different stimuli, including infection, may trigger a defect in immunoregulation in those with a genetic predisposition", It has been suggested that subsequent tissue damage might, at least in part, occur through immune complex/neutrophil-mediated mechanisms. ANCA are now recognized to play a role in the pathogenesis of some systemic vasculitidies, such as Wegener's granulomatosis and microscopic polyarteritis nodosa". There has been only one case report, however, of the presence of ANCA in Behcet's disease, although the target antigen within the neutrophil was not characterized '. We have been able to demonstrate that the ANCA in our patient's serum were directed against BPI. This is a 55 kD cytotoxic protein stored in the azurophilic granules of neutrophils. It has target specificity for lipopolysaccharide and is therefore cytotoxic to Gramnegative bacteria 6 . Antibodies to cationic protein (CAP) 57, which is identical to BPI, have been reported as an autoantigen in some patients with systemic vasculitis, although the clinical features were not given7,8.
In order to determine whether this autoantigen-antibody complex is important in the pathogenesis of vasculitis further studies are required to correlate anti-BPI antibodies to disease activity and to show whether these antibodies have any pathophysiological effects on normal neutrophils.
